Transgene Biotek Limited (TRABI) Share Price
BSE · Healthcare · Biotechnology · ISIN INE773D01018
Key metrics
- Market Cap
- ₹21 Cr
- P/E Ratio
- —
- EPS
- -0.21
- Book Value
- 1.11
- P/B Ratio
- 2.5
- ROE
- -19.73%
- ROCE
- -2.91%
- Debt / Equity
- 2.05
- Net Margin
- -782.62%
- Revenue Growth
- -18.99%
- Profit Growth
- -144.48%
- Dividend Yield
- —
- 52W High
- ₹4.50
- 52W Low
- ₹1.83
- Market Cap Band
- micro cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Transgene Biotek Limited
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
- Headquarters
- Sangareddy, India
- Promoter Holding
- 21.68%
The full Transgene Biotek Limited analysis
Create a free account to open the complete TRABI deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.